According to the incomplete statistics of the People's Daily health client, a total of 15 investment and financing incidents occurred in the field of medicine and health across the country this week, of which 4 investment and financing amounted to 300 million yuan, and the enterprises that obtained financing involved tumors, heart, stomatology, psychology, pension and other related fields.
Ying Shi Bio: Completed a $50 million Series B financing
On March 4, Info Biotechnology (Nanjing) Co., Ltd. announced that it has completed a US$50 million (over 300 million yuan) Series B financing. The round of financing was led by SDIC China Merchants, with the participation of AIHC, Shaanxi Investment Growth and Houxin Investment, and the old shareholder Enran Venture Capital continued to invest additionally. The funds raised in this round of financing will be used to accelerate the clinical trial of IN10018 products that are being promoted simultaneously in China and the United States for multiple cancer species and using different combination drug regimens.
Ying Shi Bio Research and Development and Medical Translation Center. The picture is from the official website of Ying Shi Bio
Founded in 2018, the company's core layout is the research and development of innovative drugs for the tumor fibrosis microenvironment, focusing on breakthroughs and leading the treatment of solid tumor resistance and metastases that lack treatment options.
Aoran Biotech: Hundreds of millions of yuan Series C financing
On March 4, Aoran Biotech announced the completion of a series C financing of hundreds of millions of yuan. The financing was led by Morningside Venture Capital, followed by Shanlan Capital, Silicon Harbor Capital and Kanghua Biotech, and additional investments by the original shareholders Bangqin Capital and Angel Investment shareholders. The funds raised in this financing will be mainly used for clinical product registration, product commercialization promotion, fully automatic production line expansion and new product research and development.
Founded in 2015, Aoran Bio is one of the first batch of innovative high-tech medical device enterprises focusing on real-time molecular diagnosis technology in China.
Tingsheng Technology: Completed nearly 100 million yuan of A round financing
On March 3, Tingsheng Technology announced the successful completion of the first exploratory human clinical trial of localization ICE, and completed nearly 100 million yuan of A round financing in December 2021, this round of financing was led by Yuanlai Capital, Taiyu Investment, Daoyuan Capital, Huangpu Pharmaceutical Fund followed by investment, and old shareholders Nuoyu Capital, Titanium and Capital continued to follow up with the investment. The funds raised in this round will be used for the production of clinical trial samples of intracardiac ultrasound ICE, new product development, team personnel expansion, and company site expansion.
Founded in 2017, Tingsheng Technology focuses on the research and development of the world's leading cardiac electrophysiological interventional surgical instruments, and launched the research and development of the heart 3D standardization system, an innovative interventional treatment product for cardiac arrhythmias, in January 2019.
Huagong Biology: Completed nearly 300 million yuan of B round financing
The staff of Beijing Huagong Biotechnology Co., Ltd. is doing research. The picture is from the official website of Huagong Biology
On March 3, Beijing Huagong Biotechnology Co., Ltd. announced the completion of nearly 300 million yuan of B round financing. This round of financing is jointly led by Gaorong Capital, CICC Kai Tak Fund and CICC Kaiyuan National Emerging Industry Venture Capital Guidance Fund, followed by China Kexing, Sinopharm Zhongsheng, Hongtai Fund, Aibo Qingshi, Yuanhui Capital, Yijing Capital, etc., and investment institutions such as old shareholders Materia Medica Capital and Dtton Capital and a well-known international life science industry group continue to follow suit. This round of financing will be used for R&D and upgrading, expanding core product production capacity, enriching product lines and intelligent overall solutions, and expanding international business and CDMO business.
Founded in 2018, Huagong Bio focuses on creating an original 3D cell "intelligent manufacturing" platform, providing an overall solution for the large-scale customized expansion process of cells based on 3D microcarriers, and solving the pain points of the development of the global cell industry.
Jimei Ruisheng: Completed more than 100 million yuan of Series B financing
On March 3, Jimei Ruisheng Regenerative Medicine Group announced the completion of a B round of financing of more than 100 million yuan, which was led by Shenzhen Venture Capital, and followed by Wanrong Laterite, Soochow Securities, China Merchants Securities and Gong Mingyuan. This round of funds is mainly used to promote its first-in-class cell new drug REGEND001 two clinical trials of respiratory diseases, while completing the IND declaration of renal regenerative medicine products, accelerating the research and development of the follow-up "gene-enhanced cell" product pipeline, and completing the construction of Nanchang commercial production site.
Founded in 2015, Gemmerickson focuses on precursor cell organ regeneration, with Gemmericks focusing on highly differentiated market segments with extremely high technical barriers. Based on the unique R-Clone technology platform, the team is deeply involved in the field of precursor cells, and the product research and development work has made rapid breakthroughs.
Huayi Lok Jian: Completed hundreds of millions of yuan A round of financing
On March 2, Suzhou Huayi Lok Jian Biotechnology Co., Ltd., a leading enterprise in gene therapy drug research and development, announced the completion of a series A financing of hundreds of millions of yuan. This round of financing is led by Sequoia China, followed by Sunshine Insurance, Qingsong Capital, beijing life park venture capital fund, and the old shareholders Everbright Holdings, Fruit Yingfu and China Renaissance Capital continue to support. This round of funding will be used primarily to advance the production, registration, clinical and research of the Company's lead gene therapy products, as well as to accelerate the development of the Company's products in other targeted liver and neural areas.
Founded in 2019, Huayi Lok Jian's pilot products have initially obtained good safety and efficacy data for the broad and unmet hemophilia A field.
Reed Teeth: Completed more than $60 million in financing
On March 2, Reed Medical Technology announced the completion of more than $60 million (nearly 380 million yuan) in financing. The lead investor in this round is Jinyi Capital, and the leading strategic investor in the domestic logistics industry follows the investment. This round of financing will be mainly used for the in-depth penetration of the upstream and downstream of the supply chain to further consolidate the layout of the oral medical device and consumables supply chain, and at the same time consolidate the leading position of the dental device and consumables e-commerce industry. It is reported that reed teeth have accumulated more than 100 million US dollars in financing in the past 9 months.
Founded in early 2017, Reed Dental is committed to providing one-stop oral medical equipment and consumables procurement services to customers with private dental clinics as the main target.
Mirror Technology: Completed the investment of 10 million yuan angel round
A model of Mirror Technology. The picture is from the official website of Mirror Technology
On March 2, Shenzhen Jingxiang Technology Co., Ltd. announced that it has completed the 10 million yuan angel round investment. This round of investment is led by Times Bó Lè and followed by other well-known industrial angel investors.
Founded in 2019, Mirror Technology is committed to empowering the early screening, early diagnosis, early intervention, and big data early warning management of mental and mental health problems of the public. At present, The Adult Mental Health Screening Solution of Mirror Technology has obtained the Second Class Registration Certificate of Medical Devices of the State Food and Drug Administration.
Sky & Pension: Completed $20 million A+ round of financing
On March 1, Tianhe Pension announced the completion of a $20 million (more than 100 million yuan) A+ round of financing, this round of financing was led by A round investor Changling Capital, Zhong Ding Capital followed, and A round investor Hillhouse and Wanwu continued to invest additionally. A round of investors Hillhouse, Changling and All Things all continue to increase investment in the A+ round, and this round of financing will be mainly used for the upgrading and iteration of digital platforms, the improvement of scientific and technological medical solution capabilities, and the creation of "gold standards" in the pension industry.
Founded in January 2019, Tianhe Pension is a smart pension platform company that leads the development of China's pension industry with digital technology, and has established a comprehensive service system of home, community, institutional and long-term care insurance services.
Spring Pharmaceutical: Completed nearly 100 million yuan of A round financing
On March 1, Beijing Spring Pharmaceutical Technology Development Co., Ltd. announced the completion of the A round of financing, the lead investor of this round of financing, Dongfang Fuhai, the cooperative partner of Yichuang Investment, Zhejiang Reunion, participated in the investment, and the scale of the A round of financing reached 100 million yuan.
Founded in 2004, Spring Pharmaceutical focuses on providing professional services for innovative pharmaceutical and device enterprises in the whole process of clinical research, with clinical research experience covering 18 therapeutic fields, and establishing differentiated competitive advantages in ophthalmology, oncology, nervous system diseases and other fields. By the end of 2021, the clinical research of more than 500 projects has been completed, and more than ten pharmaceutical devices have been approved for listing.
Ginovis: Completed nearly 100 million yuan Pre-A round of financing
On March 1, Beijing Gino Sanitary Matter Technology Co., Ltd. announced that it has completed the pre-A round of financing of nearly 100 million yuan led by Puhua Capital, and has now launched a series A financing for the acceleration of R&D pipelines and the industrialization of Phase III projects.
Founded in March 2011, Ginovia is a group company focusing on the research and development and industrialization of innovative vaccines, committed to the research and development of innovative vaccines for respiratory infectious diseases, the company has established a variety of dosage forms such as needles, needles, nasal sprays, and innovative vaccine research and development pipelines for more than 10 innovative vaccine products in 8 disease areas, including disease areas covering new coronavirus pneumonia, influenza, herpes zoster, respiratory syncytial virus, rabies, hand-foot-and-mouth disease, brucellosis, etc.
Flash Technology: Completed nearly 100 million yuan of A round financing
On February 28, Shenzhen Flash Volume Technology Co., Ltd. announced the completion of nearly 100 million yuan of A round financing. This round of financing was led by Fosun Chuangfu (Shenzhen) Power Technology Angel Fund, followed by Yuansheng Venture Capital, and completed by the original shareholder Zhejiang Min investment.
Founded in 2018, Flash Volume Technology is committed to providing fully automated molecular diagnostic solutions, developing an ultra-multiplex fluorescence quantitative PCR platform of "sample in- result out", and its research and development of the real-time multiplex quantitative molecular diagnosis platform FDx-1000, which realizes fully enclosed, one-click "sample in- and result out" rapid multiple nucleic acid detection, which can be widely used in infectious and infectious disease pathogen detection, accompanying diagnosis, medication guidance, identification, environmental monitoring, food safety and other fields.
Lingyi Biologics: Completed nearly 100 million yuan of Pre-A and Pre-A+ rounds of financing
On February 28, Lingyi Biotech announced the completion of nearly 100 million yuan of Pre-A and Pre-A+ rounds of financing, of which the Pre-A round was exclusively invested by Matrix Partners and the Pre-A+ round was exclusively invested by Sequoia China, promoting the improvement of the company's rare disease animal model platform and the preclinical research and development of a number of leading gene therapy pipelines.
Founded in 2021, Lingyi Bio is a leading gene therapy company with the world's leading animal model function verification platform for rare diseases, committed to source innovation, focusing on hereditary rare diseases such as metabolism, CNS, and ophthalmology.
Gebo Biotech: Completed nearly $50 million Series A financing
On February 28, Gebo Biopharma Co., Ltd. announced the completion of nearly US$50 million (more than 300 million yuan) Series A financing. This round of financing was led by Hillhouse Venture Capital, followed by Eli Lilly Asia Fund, Qiming Venture Capital and E Fund. Old shareholders Kaitai Capital, Legend Capital and Jianfeng Qiyun continue to add funds to support the company's innovative development. The funding will be used to promote R&D pipelines, upgrade the new target discovery platform, and team building. Previously, the company has completed an angel round of financing of 20 million US dollars, and the company's cumulative financing has reached nearly 70 million US dollars.
Founded in March 2021, Gebo Biotech is a new drug research and development company focusing on the degradation of molecular gum-targeted proteins, and has established a multi-dimensional protein degradation screening platform, an innovative target verification platform, a molecular gum rational design platform, and a proprietary high-activity molecular library.
Kejin Bio: Completed an angel round of financing of nearly 100 million yuan
On February 28, Wuxi Kejin Biotechnology Co., Ltd. announced the completion of an angel round of financing of nearly 100 million yuan, which was led by Power Capital, followed by Jinpu Health Fund and Wuxi Jincheng Yingyue Angel Fund. The company has also received strong support from the Management Committee of Xidong New Town Business District in Xishan District, Wuxi City, and has been supported by the construction of production bases and high-end talent subsidy policies. This round of financing is mainly used to promote the company's first rare disease product pipeline, pyruvate kinase deficiency, in China and Europe two IND filings.
Founded in January 2022, Wuxi Kejin Biotechnology Co., Ltd. is an innovative company focusing on the treatment of rare diseases and new anti-cancer drugs with gene editing technology and cell therapy.
Editor-in-charge: Qiao Jingfang